WO2018160699A1 - Biomarqueurs pour le diagnostic, la prédiction et/ou le pronostic du cancer du pancréas et utilisations correspondantes - Google Patents

Biomarqueurs pour le diagnostic, la prédiction et/ou le pronostic du cancer du pancréas et utilisations correspondantes Download PDF

Info

Publication number
WO2018160699A1
WO2018160699A1 PCT/US2018/020233 US2018020233W WO2018160699A1 WO 2018160699 A1 WO2018160699 A1 WO 2018160699A1 US 2018020233 W US2018020233 W US 2018020233W WO 2018160699 A1 WO2018160699 A1 WO 2018160699A1
Authority
WO
WIPO (PCT)
Prior art keywords
mir
pancreatic cancer
microrna
extracellular vesicles
cells
Prior art date
Application number
PCT/US2018/020233
Other languages
English (en)
Inventor
Reginald HILL
Katherine Richards
Original Assignee
University Of Notre Dame Du Lac
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Notre Dame Du Lac filed Critical University Of Notre Dame Du Lac
Publication of WO2018160699A1 publication Critical patent/WO2018160699A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Abstract

L'invention concerne un procédé pour le traitement, le diagnostic ou le pronostic du cancer du pancréas chez un sujet, comprenant l'obtention d'un échantillon contenant des vésicules extracellulaires en son sein, les vésicules extracellulaires étant sécrétées par des fibroblastes associés au cancer du pancréas. Le procédé comprend en outre la lyse des vésicules extracellulaires et la libération des micro-ARN contenus en leur sein et la quantification des micro-ARN libérés.
PCT/US2018/020233 2017-03-01 2018-02-28 Biomarqueurs pour le diagnostic, la prédiction et/ou le pronostic du cancer du pancréas et utilisations correspondantes WO2018160699A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762465429P 2017-03-01 2017-03-01
US62/465,429 2017-03-01

Publications (1)

Publication Number Publication Date
WO2018160699A1 true WO2018160699A1 (fr) 2018-09-07

Family

ID=61768427

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/020233 WO2018160699A1 (fr) 2017-03-01 2018-02-28 Biomarqueurs pour le diagnostic, la prédiction et/ou le pronostic du cancer du pancréas et utilisations correspondantes

Country Status (1)

Country Link
WO (1) WO2018160699A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023133778A1 (fr) * 2022-01-14 2023-07-20 南通大学附属医院 Cellule recombinée du cancer du pancréas pour le suivi des exosomes et son utilisation

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007081680A2 (fr) * 2006-01-05 2007-07-19 The Ohio State University Research Foundation Anomalies dans l'expression des micro-arn dans des tumeurs endocrines pancréatiques et des tumeurs à cellules acineuses
US20100144850A1 (en) * 2007-04-30 2010-06-10 The Ohio State University Research Foundation Methods for Differentiating Pancreatic Cancer from Normal Pancreatic Function and/or Chronic Pancreatitis
WO2013090556A1 (fr) * 2011-12-13 2013-06-20 The Ohio State University Procédés et compositions se rapportant à mir-21 et mir-29a, à l'inhibition d'exosome, et à la métastase cancéreuse
WO2015138426A1 (fr) * 2014-03-10 2015-09-17 Croce Carlo M Compositions et méthodes permettant de traiter la cachexie
WO2015153679A1 (fr) * 2014-03-31 2015-10-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. Dosage de microarn permettant la détection et la gestion de précurseurs de cancer du pancréas
WO2015182781A1 (fr) * 2014-05-30 2015-12-03 東レ株式会社 Kit de détection du cancer du pancréas, dispositif et méthode de détection

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007081680A2 (fr) * 2006-01-05 2007-07-19 The Ohio State University Research Foundation Anomalies dans l'expression des micro-arn dans des tumeurs endocrines pancréatiques et des tumeurs à cellules acineuses
US20100144850A1 (en) * 2007-04-30 2010-06-10 The Ohio State University Research Foundation Methods for Differentiating Pancreatic Cancer from Normal Pancreatic Function and/or Chronic Pancreatitis
WO2013090556A1 (fr) * 2011-12-13 2013-06-20 The Ohio State University Procédés et compositions se rapportant à mir-21 et mir-29a, à l'inhibition d'exosome, et à la métastase cancéreuse
WO2015138426A1 (fr) * 2014-03-10 2015-09-17 Croce Carlo M Compositions et méthodes permettant de traiter la cachexie
WO2015153679A1 (fr) * 2014-03-31 2015-10-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. Dosage de microarn permettant la détection et la gestion de précurseurs de cancer du pancréas
WO2015182781A1 (fr) * 2014-05-30 2015-12-03 東レ株式会社 Kit de détection du cancer du pancréas, dispositif et méthode de détection

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
K E RICHARDS ET AL: "Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells", ONCOGENE, vol. 36, no. 13, 26 September 2016 (2016-09-26), London, pages 1770 - 1778, XP055474728, ISSN: 0950-9232, DOI: 10.1038/onc.2016.353 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023133778A1 (fr) * 2022-01-14 2023-07-20 南通大学附属医院 Cellule recombinée du cancer du pancréas pour le suivi des exosomes et son utilisation
GB2618634A (en) * 2022-01-14 2023-11-15 Affiliated Hospital Of Nantong Univ Recombinant pancreatic cancer cell for tracking of exosomes, and use thereof

Similar Documents

Publication Publication Date Title
US11971402B2 (en) Methods and reagents for determination and treatment of organotropic metastasis
JP6980762B2 (ja) 抗腫瘍薬の調製におけるｖｃｐ阻害剤及び腫瘍溶解性ウイルスの使用
Hou et al. mTOR inhibitor rapamycin alone or combined with cisplatin inhibits growth of esophageal squamous cell carcinoma in nude mice
CN112522394B (zh) 新型外泌体释放相关靶点及其在监测和抑制肿瘤中的应用
US11466273B2 (en) Monocarboxylate transporter 4 (MCT4) antisense oligonucleotide (ASO) inhibitors for use as therapeutics in the treatment of cancer
US20210369760A1 (en) Microrna-based therapy targeted against lcp-1 positive cancers
JP2022543555A (ja) ｍｉＲＮＡ－１９３ａに関する新たな処置
US10526662B2 (en) FALZ for use as a target for therapies to treat cancer
EP3807410A1 (fr) Polythérapies comprenant un arnca alpha c/ebp
EP2606909A1 (fr) Procédé et composition pour le traitement, la prévention et le diagnostic d'un cancer contenant des cellules souches cancéreuses ou issu de celles-ci
WO2018160699A1 (fr) Biomarqueurs pour le diagnostic, la prédiction et/ou le pronostic du cancer du pancréas et utilisations correspondantes
Li et al. Co-treatment with Everolimus, an mTOR-Specific antagonist, or downregulation of ELK1 enhances the sensitivity of pancreatic Cancer cells to Genistein
US20210071180A1 (en) Microrna 584-5p compositions and methods for treating cancer
US20180221369A1 (en) Compositions and methods for treating fibrosing disorders and cancer
US20230136088A1 (en) miRNA-193a for Promoting Immunogenic Cell Death
Eisa et al. Enniatin A inhibits the chaperone Hsp90 and unleashes the immune system against triple-negative breast cancer
JP2018177658A (ja) 去勢抵抗性前立腺癌の治療
CN116212024A (zh) Ube2t抑制剂的用途及抗恶性胶质瘤的药物组合物
WO2022031859A2 (fr) Acide méthylmalonique et son métabolisme en tant que biomarqueur du cancer et cible
CN114984007A (zh) Pradx-ezh2小分子抑制剂及其在制备肿瘤治疗药物中的用途
CN115814082A (zh) 抑制hspa4在制备治疗和/或预防人乳腺癌的药物中的应用
CN116219011A (zh) Rn7sk作为肺癌诊断标志物及其应用
Su et al. Enzalutamide-induced PTH1R-mediated TGFBR2 decrease in osteoblasts contributes to resistance in bone-metastatic prostate cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18713431

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18713431

Country of ref document: EP

Kind code of ref document: A1